Sun Pharma Share Price in Focus; Gets Global Rights to Lerodalcibep Ex-US and China

Sun Pharmaceutical Industries has entered into a licensing agreement with LIB Therapeutics for lerodalcibep, a PCSK9 inhibitor used to lower LDL cholesterol, as per the exchange filing. Under the deal, Sun Pharma will handle commercialization and manufacturing across markets outside the United States and China.  

The drug is already approved in the European Union under the brand name Lyrokaul. The agreement gives Sun Pharma access to a once-monthly treatment as it expands its presence in cardiovascular medicines.  

Deal Covers Commercialisation and Manufacturing 

LIB Therapeutics will receive an upfront payment, future milestone payments and royalties linked to net sales in the territories covered by the agreement. The remaining financial terms have not been disclosed.  

Sun Pharma will also pursue approvals in markets where lerodalcibep has not yet received approval. 

Lerodalcibep Gets Monthly Dosing 

Lerodalcibep is given once a month through a 300 mg/1.2 mL injection. In the EU, Lyrokaul is approved for adults with primary hypercholesterolaemia and mixed dyslipidaemia.  

The EU product can also be kept at room temperature of up to 25°C for as long as six months after being removed from refrigeration, provided it remains in its original carton.  

PCSK9 Market Stands at $3.7 Billion 

The PCSK9 inhibitor market outside the US and China was valued at $3.7 billion in MAT Q2 2026, according to IQVIA data cited by the companies.  

It had grown at a 38% CAGR over the previous two years, while Europe accounted for $2.9 billion.  

Management Sees Cardiovascular Opportunity 

Sun Pharma Managing Director Kirti W. Ganorkar said the monthly dosing and storage flexibility add convenience for patients. He said the agreement strengthens the company's Innovative Medicines portfolio in cardiovascular care and will support wider access in its licensed markets.  

LIB Therapeutics co-founder Evan Stein said Sun Pharma's international reach and experience with innovative medicines would help bring lerodalcibep to more patients.  

Read More: Reliance Industries Share Price in Focus as FMCG Arm Raises Authorised Capital to ₹40,000 Crore! 

Sun Pharmaceutical Share Price Performance  

As of 28 September 2026, at 10:47 AM, Sun Pharmaceutical Industries share price is trading at ₹1,844 per share, reflecting a decline of 0.44% from the previous trading session. 

Conclusion 

The licensing deal gives Sun Pharma exclusive rights to lerodalcibep across markets outside the US and China. With EU approval already in place, the company will now take on commercialization and manufacturing responsibilities across its licensed territories. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.